Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Avidity Biosciences (RNA) Equity Average: 2020-2025

Historic Equity Average for Avidity Biosciences (RNA) over the last 5 years, with Sep 2025 value amounting to $1.5 billion.

  • Avidity Biosciences' Equity Average rose 13.01% to $1.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 billion, marking a year-over-year increase of 13.01%. This contributed to the annual value of $962.9 million for FY2024, which is 78.50% up from last year.
  • As of Q3 2025, Avidity Biosciences' Equity Average stood at $1.5 billion, which was up 22.11% from $1.3 billion recorded in Q2 2025.
  • Avidity Biosciences' Equity Average's 5-year high stood at $1.5 billion during Q3 2025, with a 5-year trough of $275.3 million in Q2 2021.
  • In the last 3 years, Avidity Biosciences' Equity Average had a median value of $1.0 billion in 2024 and averaged $988.2 million.
  • Data for Avidity Biosciences' Equity Average shows a peak YoY spiked of 187.59% (in 2024) over the last 5 years.
  • Avidity Biosciences' Equity Average (Quarterly) stood at $388.2 million in 2021, then climbed by 23.03% to $477.5 million in 2022, then grew by 6.61% to $509.1 million in 2023, then spiked by 187.59% to $1.5 billion in 2024, then climbed by 13.01% to $1.5 billion in 2025.
  • Its Equity Average was $1.5 billion in Q3 2025, compared to $1.3 billion in Q2 2025 and $1.4 billion in Q1 2025.